Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,891 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Cancer Patients Clear all
Recruiting Phase 1Phase 2 Interventional

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

NCT04503265
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Breast Cancer, Ovarian Cancer, Homologous Recombination Deficiency, Prostate Cancer, Pancreatic Cancer
Interventions
AMXI-5001:Dose Escalation Phase I, AMXI-5001:Dose Expansion Phase II
Drug
Lead sponsor
AtlasMedx, Incorporated
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Oct 31, 2026, 2:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

NCT01931644
View directory record Official record
Conditions
All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
17,667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 31, 2026, 2:06 PM EDT
Not listed No phase listed Observational

Analyzing Clinical Trial Experiences of Prostate Cancer Patients

NCT05411354
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Power Life Sciences Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 31, 2026, 2:06 PM EDT
Completed Phase 2 Interventional Results available

Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer

NCT00089609
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Docetaxel, Thalidomide, Prednisone, bevacizumab, polymorphism analysis, immunoenzyme technique, laboratory biomarker analysis, pharmacological study
Drug · Biological · Genetic + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 20, 2018 · Synced Oct 31, 2026, 2:06 PM EDT
Completed Phase 3 Interventional Results available

Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer

NCT00833248
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix, Goserelin, Bicalutamide
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
19
States / cities
Birmingham, Alabama • Homewood, Alabama • Anchorage, Alaska + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Oct 31, 2026, 2:06 PM EDT
Completed Phase 1Phase 2 Interventional

Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer

NCT00004211
View directory record Official record
Conditions
Prostate Cancer
Interventions
PSA RNA-pulsed dendritic cell vaccine
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Oct 31, 2026, 2:06 PM EDT
Active, not recruiting Phase 2 Interventional

Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy

NCT01410942
View directory record Official record
Conditions
Prostate Cancer
Interventions
Placebo, Methylphenidate, Counseling Sessions, Sham Exercise, Standardized Exercise Intervention Program, Cognitive Behavioral Therapy (CBT)
Other · Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 31, 2026, 2:06 PM EDT
Terminated Phase 2 Interventional Results available

Green Tea Extract in Treating Patients With Low-Risk Prostate Cancer

NCT01928485
View directory record Official record
Conditions
Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
Interventions
active surveillance, Sunphenon, laboratory biomarker analysis, Questionnaire Administration
Other · Drug
Lead sponsor
Sanjay Gupta PhD
Other
Eligibility
45 Years to 85 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 31, 2026, 2:06 PM EDT
Completed No phase listed Observational

Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide

NCT02228265
View directory record Official record
Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, PSA Progression, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Cytology Specimen Collection Procedure, Enzalutamide, Laboratory Biomarker Analysis
Other · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 28, 2020 · Synced Oct 31, 2026, 2:06 PM EDT
Recruiting Phase 2 Interventional

Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

NCT05766371
View directory record Official record
Conditions
Castrate Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Carcinoma
Interventions
Pembrolizumab, 177Lu-PSMA-617
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 31, 2026, 2:06 PM EDT
Completed Phase 3 Interventional Results available

Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer

NCT00365105
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Metastatic Cancer, Pain, Prostate Cancer
Interventions
Calcium, Vitamin D, zoledronic acid, Sm-153, Sr-89
Dietary Supplement · Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
147
States / cities
Mobile, Alabama • Burbank, California • Carmichael, California + 116 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2024 · Synced Oct 31, 2026, 2:06 PM EDT
Completed Phase 1 Interventional

Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer

NCT01186601
View directory record Official record
Conditions
Neoplasms
Interventions
PET tracer (BAY94-9392)
Drug
Lead sponsor
Lantheus Biosciences Ltd.
Industry
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Oct 31, 2026, 2:06 PM EDT
Completed Phase 2 Interventional Results available

Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

NCT01503229
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Adenocarcinoma
Interventions
Abiraterone Acetate, Laboratory Biomarker Analysis, Pharmacological Study, Prednisone
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Oct 31, 2026, 2:06 PM EDT
Completed Phase 2 Interventional

Lycopene in Treating Patients With Metastatic Prostate Cancer

NCT00068731
View directory record Official record
Conditions
Prostate Cancer
Interventions
lycopene
Dietary Supplement
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
18
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 31, 2026, 2:06 PM EDT
Completed Phase 2 Interventional Results available

Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations

NCT03570619
View directory record Official record
Conditions
Metastatic Castration Resistant Prostate Cancer, Metastatic Cancer, Solid Tumor
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
8
States / cities
San Diego, California • San Francisco, California • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 31, 2026, 2:06 PM EDT
Completed Phase 1 Interventional

High-Intensity Focused Ultrasound in Treating Patients With Locally Recurrent Prostate Cancer

NCT00030277
View directory record Official record
Conditions
Prostate Cancer
Interventions
high-intensity focused ultrasound ablation
Procedure
Lead sponsor
Focus Surgery
Industry
Eligibility
40 Years to 80 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
2
States / cities
Indianapolis, Indiana • Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 31, 2026, 2:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Androgen Deprivation Therapy on Cardiovascular Function in Prostate Cancer

NCT03275181
View directory record Official record
Conditions
Prostate Cancer
Interventions
Transthoracic Echocardiography, Arterial blood pressure, Submaximal Exercise
Diagnostic Test
Lead sponsor
Kansas State University
Other
Eligibility
21 Years to 80 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Manhattan, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 31, 2026, 2:06 PM EDT
Completed Not applicable Interventional

Soy Isoflavones in Treating Patients With Recurrent Prostate Cancer or Rising Prostate-Specific Antigen

NCT01682941
View directory record Official record
Conditions
Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
Arm I Soy Bread, Arm II Soy-Almond Bread
Dietary Supplement
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 31, 2026, 2:06 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer

NCT01057810
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ipilimumab, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Male only
Enrollment
837 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
42
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Oct 31, 2026, 2:06 PM EDT
Withdrawn Not applicable Interventional

Virtual Prostate Biopsy Protocol for Patients on Active Surveillance and at Risk of Prostate Cancer

NCT03823001
View directory record Official record
Conditions
Prostate Cancer
Interventions
virtual biopsy (VB) monitoring protocol
Diagnostic Test
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 20, 2022 · Synced Oct 31, 2026, 2:06 PM EDT
Completed Not applicable Interventional

Personal Patient Profile Prostate (P4) Randomized, Multisite Trial

NCT00692653
View directory record Official record
Conditions
Prostate Cancer
Interventions
P4
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
21 Years and older · Male only
Enrollment
498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Augusta, Georgia • Philadelphia, Pennsylvania • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Oct 31, 2026, 2:06 PM EDT
Not yet recruiting No phase listed Observational

Determining Patterns In Trial Experiences of Recurrent Prostate Cancer Patients

NCT06070272
View directory record Official record
Conditions
Recurrent Prostate Cancer
Interventions
Not listed
Lead sponsor
Power Life Sciences Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 31, 2026, 2:06 PM EDT
Active, not recruiting Phase 2 Interventional

Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

NCT02703623
View directory record Official record
Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Abiraterone Acetate, Apalutamide, Cabazitaxel, Carboplatin, Ipilimumab, Laboratory Biomarker Analysis, Prednisone
Drug · Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
3
States / cities
Houston, Texas • Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 31, 2026, 2:06 PM EDT
Withdrawn Phase 1 Interventional

Genistein in Treating Patients With Stage II, Stage III, or Stage IV Prostate Cancer

NCT00005827
View directory record Official record
Conditions
Prostate Cancer
Interventions
genistein
Dietary Supplement
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
40 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2012 · Synced Oct 31, 2026, 2:06 PM EDT